Innovative Test Enhances Quality Control in Allergy Treatments
A novel immunoassay developed by the Paul Ehrlich Institute allows precise measurement of allergoids in allergy medicines, improving quality control and standardization of allergy immunotherapy products.
A multidisciplinary team from the Allergology and Veterinary Medicine Divisions at the Paul Ehrlich Institute has developed a groundbreaking laboratory assay that allows for the precise quantification of adjuvanted allergoids within finished allergy medicinal products. Previously, assessing the content of these complex formulations was challenging due to their intricate structures, which contain both allergen-modifying compounds (allergoids) and adjuvants, restricting analysis to intermediary production stages. The newly introduced testing method marks a significant breakthrough in the quality assurance of allergy immunotherapy (AIT) medications.
Allergy immunotherapy involves using sensitized allergens to train the immune system towards tolerance, with allergoids being chemically modified allergens designed for this purpose. Accurate dosing and proven efficacy depend heavily on knowing the exact allergoid concentration, yet until now, this measurement in final pharmaceutical formulations was not feasible. The novel immunoassay employs highly specific antibodies in an enzyme-linked detection system, enabling accurate, reliable detection of allergoids directly in medicinal products. This method can effectively eliminate the need for animal testing and enhances the standardization and quality control processes.
The research, published in the journal "Allergy," demonstrates that this assay can consistently measure allergen content in grass pollen allergoids, which are common components in allergy therapy. The project was led by Dr. Frank Führer from the Paul Ehrlich Institute, emphasizing the importance of this advancement for regulatory oversight and manufacturing quality assurance. The implementation of such precise testing protocols promises to improve the consistency, safety, and efficacy of allergy treatments, benefiting both manufacturers and patients.
This development reinforces the Paul Ehrlich Institute's role in ensuring the safety and quality of allergy immunotherapies, responding to regulatory requirements by providing a sophisticated tool for batch testing and standardization. Source: https://medicalxpress.com/news/2025-06-quality-allergy-therapeutics.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Harnessing Digital Technology to Revolutionize Pediatric Nursing
Explore how digital technology, including AI, wearable sensors, and virtual tools, is transforming pediatric nursing by enhancing safety, personalization, and overall patient experience.
Innovative AI Techniques Reveal How We Make Decisions
New AI-based research uncovers the actual decision-making strategies of humans and animals using small, interpretable neural networks, offering insights into suboptimal and individual strategies in real-world scenarios.
Innovative Marker FXYD2 Enhances Identification of Functional Stem Cell-Derived Islets for Diabetes Treatment
A new discovery of the FXYD2 marker improves the identification of functional stem cell-derived islets, advancing diabetes cell therapy accuracy and safety.
The Critical Role of Sleep in Women's Long-Term Heart Health During Menopause
Sleep quality during menopause plays a crucial role in determining women’s long-term cardiovascular health. A recent study underscores the importance of adequate sleep for preventing future heart risks in midlife women.